1370534-66-9

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 1356386-26-9 2-(4-bromo-2-fluorophenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole 
• 73183-34-3 bis(pinacol)diborane 
• 1370534-54-5 2-(6-bromopyridin-3-yl)-6-(trifluoromethyl)-1H-benzimidazole 

Downstream Products

• 1388144-56-6 (1-{5-[3-fluoro-4-(5-trifluoromethyl-1H-benzoimidazol-2-yl)phenyl]pyrazin-2-yl}piperidin-4-yl)acetic acid ethyl ester 
• 1438244-63-3 3-(5-(3-fluoro-4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)phenyl)pyrimidin-2-yloxy)cyclobutanecarboxylic acid 
• 1438250-35-1 ethyl 3-(5-(3-fluoro-4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)phenyl)pyrimidin-2-yloxy)cyclobutanecarboxylate 

Relevant academic research and scientific papers

IMIDAZOLE DERIVATIVES

Disclosed herein are novel imidazole derivative compounds i.e., benzimidazole and aza-benzimidazole derivatives that act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperiipidemia, diabetes mellitus and obesity. Further disclosed are methods of treating various DGAT1 -related diseases, and the use of such imidazole compounds as described herein in the manufacture of a medicament for such treatment.

COMPOUNDS AS DGAT-1 INHIBITORS

Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.